Hospital Readmission Rate
Primary
· 30 days
Rate of readmission to the hospital after abscess drainage.
| Group | Value | 95% CI |
|---|---|---|
| Arm A (8-Day) 30-day Readmission Rate | 0 | |
| Arm B (4-Day) 30-day Readmission Rate | 0 |
Last reviewed · How we verify
NCT03795194
Antibiotic Duration in Post-appendectomy Abscess
Terminated
Phase 4
Results posted
Last updated 8 March 2024
What this trial tests
Phase 4 trial testing ampicillin/clavulanate in Complicated Appendicitis in 7 participants. Terminated before completion.
Timeline
1 May 2019
Primary endpoint
15 December 2021
15 December 2021
15 December 2021
Quick facts
| Lead sponsor | Phoenix Children's Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 7 |
| Start date | 1 May 2019 |
| Primary completion | 15 December 2021 |
| Estimated completion | 15 December 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- ampicillin/clavulanate — full drug profile →
Conditions studied
- Complicated Appendicitis — all drugs for Complicated Appendicitis →
- Perforated Appendicitis — all drugs for Perforated Appendicitis →
Sponsor
Phoenix Children's Hospital
Who can join
Adults 2 to 17, any sex, with Complicated Appendicitis or Perforated Appendicitis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Sponsor's own description
This is a randomized study of patients 2-17 years old who are diagnosed with perforated appendicitis and develop an abscess after laparoscopy that is subsequently drained. Patients will be randomized to either receive an 8-day or a 4-day course of antibiotics. The aim of this study is to determine whether duration of antibiotic treatment at discharge demonstrates significant differences in clinical outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03795194
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Phoenix Children's Hospital trials
Trials by the same sponsor.
- NCT06372249 — A Clinical Trial of Soluble Fiber for Asthma · Phase 2 · recruiting
- NCT05925075 — Point of Care Lung Ultrasound in Preterm Infants with Respiratory Distress · enrolling by invitation
- NCT05563610 — Oral Penicillin Challenge and Allergy De-labeling in Children · Phase 4 · terminated
- NCT04344652 — Photoscreening for Retinoblastoma · NA · withdrawn
- NCT04040452 — Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03795194 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Phoenix Children's Hospital
- Last refreshed: 8 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03795194.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing